Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $132.52, giving the company a market capitalization of 165.86B. It carries a P/E multiple of 20.04 and pays a dividend yield of 2.3%.
During the trading session on 2026-04-23, Gilead Sciences(GILD) shares reached a daily high of $134.68 and a low of $132.52. At a current price of $132.52, the stock is 0.0% higher than the low and still -1.6% under the high.
Trading activity shows a volume of 3.87M, compared to an average daily volume of 5.14M.
The stock's 52-week range extends from a low of $93.37 to a high of $157.29.
The stock's 52-week range extends from a low of $93.37 to a high of $157.29.
GILD News
In an SEC filing after hours on Monday, the company said it has discontinued its Phase 3 STAR-121 study in metastatic non-small cell lung cancer after an interi...
Advertisement Why Gilead Sciences (GILD) Is Drawing Investor Attention Now With no single headline event driving the move, Gilead Sciences (GILD) is attractin...
Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of cou...
Analyst ratings
75%
of 32 ratingsMore GILD News
In a regulatory filing, Arcus Biosciences (RCUS) announced the discontinuation of the Phase 3 STAR-121 study, which is being conducted in collaboration with Gil...
Leerink lowered the firm’s price target on Arcus Biosciences to $47 from $49 and keeps an Outperform rating on the shares. The firm sees the end of Arcus’ (RCUS...
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Gilead Sciences (NasdaqGS:GILD) has received all required regulatory approvals to close its US$7.8b acquisition of Arcellx. The company also announced an agree...
White-collar workers in the U.S. have been hit especially hard by layoffs so far this year, and the trend appears to be getting worse. While 2025 already saw a...
Earlier this week, Gilead Sciences announced expanded collaborations with the U.S. State Department, PEPFAR, and The Global Fund to widen access to its twice-ye...
Gilead Sciences (GILD) announced that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx (ACLX) and that G...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.